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Abstract
Background: 15-hydroxyprostaglandin dehydrogenase (15-PGDH, EC 1.1.1.141) is the key enzyme for the inactivation of
prostaglandins, regulating processes such as inflammation or proliferation. The anabolic pathways of prostaglandins,
especially with respect to regulation of the cyclooxygenase (COX) enzymes have been studied in detail; however, little is
known about downstream events including functional interaction of prostaglandin-processing and -metabolizing enzymes.
High-affinity probes for 15-PGDH will, therefore, represent important tools for further studies.
Principal Findings: To identify novel high-affinity inhibitors of 15-PGDH we performed a quantitative high-throughput
screen (qHTS) by testing .160 thousand compounds in a concentration-response format and identified compounds that
act as noncompetitive inhibitors as well as a competitive inhibitor, with nanomolar affinity. Both types of inhibitors caused
strong thermal stabilization of the enzyme, with cofactor dependencies correlating with their mechanism of action. We
solved the structure of human 15-PGDH and explored the binding modes of the inhibitors to the enzyme in silico. We found
binding modes that are consistent with the observed mechanisms of action.
Conclusions: Low cross-reactivity in screens of over 320 targets, including three other human dehydrogenases/reductases,
suggest selectivity of the present inhibitors for 15-PGDH. The high potencies and different mechanisms of action of these
chemotypes make them a useful set of complementary chemical probes for functional studies of prostaglandin-signaling
pathways.
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Introduction
Eicosanoids are arachidonic acid derivatives that comprise
distinct functional classes including prostaglandins (PGs), lipoxins
and leukotrienes [1–3]. These bioactive fatty acids control a
multitude of physiological functions including inflammation and
differentiation. Dysregulation of the enzymes responsible for the
generation and metabolism of active prostaglandins and lipoxins is
associated with malignant transformation and progression in a
variety of cancer types, such as breast, colon, lung and bladder
cancers [4–10]. The intracellular levels of prostaglandins are
controlled mainly by the interplay between the cyclooxygenase
enzymes (COX-1 and COX-2) on the one hand, and 15-
hydroxyprostaglandin dehydrogenase (15-PGDH, EC 1.1.1.141)
and other inactivating enzymes, on the other. COX-1 and COX-2
are bifunctional enzymes that, through their fatty acid cycloox-
ygenase- and prostaglandin hydroxyperoxidase activities, ultimate-
ly catalyze the generation of prostaglandin H2 (PGH2) from
arachidonic acid [11]. The other prostaglandins are then
generated and transformed into one another by several isomerases
and synthases, producing, e.g., prostacyclin (PGI2) or thrombox-
ane A2 (TX) [11,12]. The wide variety of effects of prostaglandins
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13719in many different cell types derives from binding to a variety of
mainly G-protein coupled receptors, of which eleven are currently
known [12]. In addition, prostaglandins also interact with nuclear
hormone receptors, thereby eliciting direct transcriptional effects
[13,14].
15-PGDH represents the key enzyme in the inactivation of a
number of active prostaglandins, leukotrienes and hydroxyeicosa-
tetraenoic acids (HETEs) (e.g., by catalyzing oxidation of PGE2 to
15-keto-prostaglandin E2, (15k-PGE)) [15]. Thus far, two forms of
15-PGDH have been identified: NAD
+-dependent type-I 15-
PGDH, and the NADP
+-dependent type-II 15-PGDH [15], also
known as carbonyl reductase 1 (CBR1, SDR21C1) [16,17]. The
preference for NADP
+ and the high Km values of CBR1 for most
PGs suggest that the majority of the in vivo activity can be
attributed to type-I 15-PGDH [15]. Human type-I 15-PGDH is
encoded by the HPGD gene and belongs to the evolutionarily
conserved superfamily of short-chain dehydrogenase/reductase
enzymes (SDRs) [18], within which it is classified as SDR36C1
[17]. The enzyme has been purified from human placenta and its
primary structure determined by Edman degradation [19]; it was
subsequently cloned [20] and characterized as a homodimer with
subunits of a size of 29 kDa [20,21].
The critical importance of 15-PGDH for the inactivation of
prostaglandins makes the enzyme an attractive target for studying
the details of interactions and signaling events in inflammation and
cancer. However, all inhibitors that have been identified so far lack
potency and specificity. Several thiazolidinedione peroxisome
proliferator-activated receptor c (PPARc) agonists, including
pioglitazone and ciglitazone, have been shown to inhibit
recombinant human placental 15-PGDH. Ciglitazone showed an
IC50 of 2.7 mM [22], while an optimized derivative, CT-8, had a
Ki of ,90 nM [23]. Other clinically approved drugs that also act
as inhibitors of 15-PGDH with micromolar potencies include non-
steroidal anti-inflammatory drugs (NSAIDs) and COX inhibitors,
e.g., indomethacin, sulindac, and niflumic acid [22]. Finally, a
group of compounds called sulphasalazines have also been shown
to inhibit human 15-PGDH, with the most effective compound,
CAY10397, having a Ki of 110 nM [24].
Here we describe the identification of chemotypes that potently
inhibit human 15-PGDH, with either competitive or noncompet-
itive kinetics, and strongly stabilize the enzyme in a cofactor-
dependent manner. The lead compounds show remarkable
selectivity based on accumulated data from a large number of
high-throughput screens against a wide range of targets. The
determination of the crystal structure of 15-PGDH, also reported
in this work, enabled us to propose a binding mode for the
competitive inhibitor in the active site pocket that confirms its
mechanism of inhibition. For the other inhibitors, the observations
from the 15-PGDH crystal structure characterized the mechanism
of inhibition as being noncompetitive.
Results
High-throughput identification of inhibitors of 15-PGDH
To screen for inhibitors in a high-throughput format, we
adopted the standard assay used for this enzyme which involved
monitoring the increase in sample fluorescence corresponding to
the conversion of the non-fluorescent NAD
+ cofactor into the
fluorescent NADH upon oxidation of the 15-PGDH substrate 15-
hydroxyprostaglandin type-E2 (PGE2) (Figure 1). The assay was
miniaturized to a 4-mL volume in 1536-well format: enzyme (3 mL)
was dispensed first, followed by a pintool transfer of library
compounds dissolved in DMSO. After equilibration, a substrate
dispense (1 mL) initiated the enzymatic reaction (see Materials and
Methods, for detailed protocol description). A robotic validation
run consisting of a concentration-response screen of the LO-
PAC
1280 library, performed in triplicate, yielded excellent assay
statistics and hit reproducibility (supplementary information
Figures S1A and S1B). The concentration-response screen of the
entire collection comprising 895 1536-well plates was completed in
5 days. The Z’ screening factor [25] associated with each plate
remained high and stable throughout the screen (average
Z’=0.86, Figure 1A). A concentration response of the control
inhibitor GW5074, identified in an earlier pilot screen (PubChem
AID 894, supplementary information Figure S1C), added as a 16-
point dilution series in duplicate between 57.5 mM and 3.5 nM
into the second column of every assay plate displayed consistent
inhibition throughout the screen (supplementary information
Figure S1D): the average IC50 was 10.4 mM and the associated
minimum significant ratio was 1.5, indicating a highly stable run
according to the definition given by Eastwood and co-workers
[26]. The hits identified ranged in inhibitory potency from
submicromolar to double-digit micromolar (Figure 1B). In order to
progress only the highest-confidence primary screening hits to the
subsequent investigations, samples exhibiting weak/noisy respons-
es, as well as those representing potential false positives, were
eliminated during the initial analysis. The testing of each library
compound in dose-response mode (see example in Figures 1C and
1D) permitted a detailed examination of the type and quality of the
inhibition response (IC50, concentration-response curve shape,
efficacy, presence of asymptotes). Hits associated with low-efficacy
(,40% maximum inhibition), incomplete curves, as well as those
displaying only a single-point inhibition at the top concentration
tested were eliminated from further consideration. Similarly, the
collection of real-time kinetic data allowed the autofluorescence of
each compound to be evaluated by comparing the initial
fluorescence read at top concentration with the mean value of
uninhibited assay controls: compounds whose top-concentration
initial well fluorescence exceeded six standard deviations over the
mean were flagged as potential autofluorescent artifacts [27,28]
(see example in supplementary information Figure S1E). The
complete screening and followup results are available in PubChem
(PubChem Assay ID 894).
Re-testing of HTS hits
Similarity clustering of the high-confidence compounds result-
ing from the above triaging process performed using LEAD-
SCOPE (Columbus, OH, USA) yielded 23 clusters and 15
singletons. A total of 87 representative members were chosen for
re-sourcing and re-testing in a miniaturized screening assay as 24-
point dilution series [29] where the majority of the compounds
confirmed. Visual inspection of these retested hits (supplementary
information Table S1, a subset shown in Figure 2) allowed further
merging of clusters. Based on these clusters, 50 representative
compounds that fulfilled stringent criteria for confidence (i.e.,
complete concentration-response curves comprising two clear
asymptotes, $80% max. inhibition, and R
2.0.9) were selected for
further evaluation in the protein stabilization experiments
described below.
Compound stabilization of 15-PGDH
To investigate the ability of the inhibitors to thermally stabilize
15-PGDH, differential scanning fluorimetry (DSF [30]) was
performed on the above 50 prioritized hits in the absence and in
the presence of the cofactor in its oxidized or reduced state (NAD
+
or NADH, respectively) (Figures 3 and 4). The melting point, Tm,
of ligand-free 15-PGDH at pH 8.0 was 41.260.3uC (Figure 4A).
The stability was increased by more than 4uC in the presence of
Inhibitors of Human 15-PGDH
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+ (Tm=45.960.1uC) and by more than 10uC in the presence
of NADH (Tm=52.560.4uC). The substrate PGE2 failed to
stabilize without cofactor, but stabilized by 2.4uC in the presence
of NAD
+ (Figure 4A). Interestingly, no stabilization was observed
in the presence of NADH. Similarly to PGE2, none of the
inhibitors stabilized the protein in the absence of cofactor
(Figure 4A and supplementary information Table S1), suggesting
that the cofactor may be necessary for the enzyme to assume a
ligand-competent conformation. This observation is also in
general concordance with the ordered bi-bi mechanism of the
enzymatic reaction of short-chain dehydrogenases including 15-
PGDH [31]. In the presence of cofactor, the 50 selected hits
elicited a range of thermal stability enhancements up to 12.2uCi n
the presence of NAD
+ and up to 13.5uC in the presence of NADH
(expressed as a shift in the transition midpoint temperature, DTm)
(Figure 3). A correlation between the DTm and the inhibitory
potency has been shown in a number of protein-ligand systems,
particularly for kinases [32–34]. In the case of 15-PGDH, the
correlation between inhibitory pIC50s and DTm in the presence of
cofactor appears to depend on chemotype: across the multiple
clusters the correlation is generally weak (Figures 3A and 3B),
while for individual chemotype clusters a meaningful correlation is
observed. For the largest cluster 1, a moderate correlation is
apparent in the presence of NAD
+, while the correlation in the
presence of NADH is more robust (R
2=0.886): in general,
compounds in this cluster show greater Tm shifts with NADH than
with NAD
+, as exemplified by the most potent analogue,
compound 13, [1-(3-methylphenyl)-1H-benzimidazol-5-yl)(piper-
idin-1-yl)methanone (a.k.a. ML148), (IC50 of 56 nM, DTm=
7.360.2uC or 13.560.9uC with NAD
+ or NADH, respectively).
Compound 72 (a.k.a. ML149), belonging to a different cluster,
showed a similar profile with a significantly larger DTm in the
presence of NADH. Conversely, members of the smaller cluster 5
showed the reverse profile: the most potent analogue 61 (a.k.a.
ML147) gave an IC50 of 141 nM and Tm shifts of 12.260.1uCo r
2.960.5uC with NAD
+ or NADH, respectively.
Verification of inhibitor activity after re-synthesis
The contrasting stabilization profiles alerted us to the possibility
of differing mechanisms of inhibition, and we selected compounds
13, 61 and 72 for further study. In order to definitively confirm
identity and activity and to provide high quality material for in-
depth kinetic studies, these three compounds were re-synthesized
(see Materials and Methods). The effects of the re-synthesized
compounds on the protein stability (Figure 4A) were found to be
similar to the results obtained previously. To achieve an optimal
signal window in the detailed kinetic measurements with the new
compounds, a higher enzyme concentration was employed and the
reactions were run at a lower percent substrate conversion than
used in both the qHTS and the re-tests. As a result, higher
apparent potencies were observed for all three compounds
(Figure 4B): The IC50 for compound 13 was 7.960.8 nM,
Figure 1. Quantitative high-throughput screen of 15-PGDH. A. Plot of the Z’ factor associated with each plate, showing high stability over the
entire duration of the screen (completed in five days). The average Z’ was 0.86. B. Hit frequency for the library of tested compounds, measured as the
distribution of compounds according to binned potencies. C. Typical effect of a non-fluorescent screening hit (inhibitor 13, titrated between 3.5 nM
and 57.5 mM) on the time course of NAD
+-reduction upon addition of PGE2. D. Dose-dependent reduction in enzyme activity caused by compound
13, as detected during the screen.
doi:10.1371/journal.pone.0013719.g001
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for compounds 61 and 72, respectively, values of IC50 of 26.462.4
and 15.061.2 nM were determined (compared to 141 nM and
82 nM, respectively). All three compounds caused a maximum of
100% inhibition (Figure 4B).
Catalytic constants in presence of inhibitors
In order to explore the mechanisms of action of 13, 61 and 72,
we determined the dependence of the enzyme activity on the
PGE2 substrate and NAD
+ cofactor concentrations, first in the
absence of inhibitor, and then at inhibitor concentrations close to
their IC50, respectively (Table 1). The Michaelis constant, Km, for
PGE2 was calculated from the data as 5.560.6 mM, comparing
favorably with previously published values [21,35,36]. The
maximal rate, Vmax, for the oxidation of PGE2 was 28.1 mmol/
(min?mg), and the catalytic constant, kcat, was about 14 per second;
the catalytic efficiency, kcat/Km, was 2.5?10
6. Compound 61 had
almost no effect on the Vmax (Figure 4C), while it caused an
increase in the Km, by 100% at 10 nM and 3-fold at 50 nM,
suggesting a competitive mechanism of inhibition with respect to
PGE2 [37]. Global fitting of the results to the four possible modes
of inhibition (competitive, uncompetitive, noncompetitive and
mixed-type inhibition) returned the highest probability for the
mixed-type mode (Table 2). However, the fitting results are also
consistent with a competitive mode for inhibition by compound
61, particularly when the residual Chi
2 value for this mode is
compared to those of the other two compounds. Together with the
observation from the Lineweaver-Burk analysis of the data (inset in
Figure 4C), the most consistent mode of inhibition for compound
61 is competitive inhibition with respect to the substrate PGE2.
On this basis, considering the concentration of the substrate in the
experiment, the observed IC50 corresponds to an inhibition
constant, Ki, of approximately 5 nM [38].
In contrast, both compounds 13 and 72 decreased the
maximum rate of 15-PGDH in titrations of PGE2 (Table 1).
Applied at a concentration of 10 nM, compound 13 decreased
Vmax by 25% (20 nM of the compound reduced Vmax to less than
half; Figure 4D), while compound 72 caused a loss of
approximately 50% in maximum activity. Compound 13
additionally also reduced the apparent Km by half at a
concentration of 10 nM, suggesting that the affinity of the enzyme
for the substrate was increased by the inhibitor, consistent with a
mode of uncompetitive or mixed-type inhibition. Because both
Figure 2. IC50 from re-testing for selected inhibitors of human
15-PGDH identified in the quantitative high-throughput
screen. Shown are the IC50 values for select compounds arranged by
cluster number, along with their PubChem Chemical Identifiers (CID).
doi:10.1371/journal.pone.0013719.g002
Figure 3. Correlation between thermal stabilization of 15-PGDH in presence of NAD
+ (A) or NADH (B) and inhibitory pIC50 for
screening hits from different structural clusters. Thermal stabilization is expressed as a shift in the midpoint of the unfolding transition of the
protein (DTm). DTm and pIC50 (-log(IC50) values are means of at least three independent measurements. The inhibitors are represented by color-coded
symbols according to their chemical clusters, respectively (supplementary information Table S1): blue, cluster 1; dark green, cluster 2; orange, cluster
3; purple, cluster 4; light blue, cluster 5; light green, cluster 8; grey, cluster 9; dark yellow, cluster 11; red, singletons (a Tm could not be determined for
the tested compounds in clusters 6, 7 & 10). The dotted line in each graph A & B denotes correlations for the compounds in cluster 1, respectively.
Numbers within the graphs assign the positions for the inhibitors of special interest (see text).
doi:10.1371/journal.pone.0013719.g003
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dependence of substrate and inhibitors, without cofactor (grey bars), and in presence of NAD
+ (light blue bars) as well as in presence of NADH (purple
bars). Shown are sets of these data, respectively, for each of the tested compounds as denoted on the Y axis. Bars represent averages of three
independent experiments, with standard deviations displayed as error bars. B. Inhibitor dose-dependent reduction of the enzyme activity caused by
compounds 13 (black triangles), 72 (blue squares) and 61 (red diamonds), respectively. Plotted values are means of three independent experiments,
with standard deviations displayed as vertical error bars. Dashed or dotted lines, in colors corresponding to the data points, result from least-squares
non-linear fitting of the data to the Hill equation (see Materials & Methods), respectively. C&D .Michaelis-Menten plots of the enzyme activity at
varying concentrations of substrate, PGE2, in absence of inhibitor (black symbols) or in presence of compounds 61 (C)o r13 (D) at concentrations
close to (blue symbols) or above (red symbols) their IC50 values, specified in table 3. The inset graph in D shows the data from the main graph as
Lineweaver-Burk plot, demonstrating competitive inhibition from independence of the Y-axis intercept (1/Vmax) of the inhibitor concentration. All
values are means of three independent measurements; standard deviations are displayed as vertical error bars.
doi:10.1371/journal.pone.0013719.g004
Table 1. Investigation of the mechanism of action for selected inhibitors of human 15-PGDH.
Conc. [nM] Titration of PGE2 Titration of NAD
+
Km [mM]
Vmax[mmol/
(min6mg)]
kcat
[1/sec]
kcat/Km
[610
6] Km [mM]
Vmax [mmol/
(min6mg)]
kcat
[1/sec]
kcat/Km
[610
6]
13 10.0
20.0
3.760.5
2.860.4
21.3
12.6
10.360.3
6.160.2
2.8
2.1
10.760.6
8.960.8
17.5
8.2
8.560.1
4.060.1
0.8
0.4
72 4.0
10.0
5.661.1
6.460.6
22.8
15.4
11.160.5
7.560.2
2.0
1.2
n.d. n.d. n.d. n.d.
61 10.0
50.0
7.560.5
13.561.3
29.0
25.6
14.160.2
12.460.3
1.8
0.9
17.060.8
11.161.2
21.1
10.2
10.360.1
5.060.1
0.6
0.4
PGE2 5.560.6 28.1 13.660.3 2.5
NAD
+ 15.860.9 21.2 10.360.1 0.7
doi:10.1371/journal.pone.0013719.t001
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efficiency, kcat/Km, was observed with this compound. In contrast,
Compound 72 showed no effect on the Km, and consequently also
caused a reduction in the catalytic efficiency of the enzyme [37].
Comparative data fitting made a noncompetitive or mixed-type
mode most likely for compound 72, while the data for compound
13 are consistent with noncompetitive, uncompetitive or mixed-
modes (Table 2).
The effects of compounds 13 and 61 on the rate constant and
catalytic efficiency of NAD
+ reduction were investigated: The Km
for NAD
+ was lower than for PGE2 (15.860.9 mM), comparing
favorably with published values [21]; the catalytic efficiency, kcat/
Km, was determined as 0.7?10
6 (Table 1). The decrease in the
maximum rate of NAD
+ reduction by compound 13 at 20 nM was
similar to its effect on the conversion of the substrate PGE2: the
Vmax was decreased by approximately 60% and the Km for NAD
+
by ,45%. Taken together, these data suggest that compound 13
acts noncompetitively or in a mixed-type mode with respect to the
substrate while uncompetitively with respect to the cofactor. For
compound 61, on the other hand, a difference between the
influence on PGE2 oxidation and on NAD
+ reduction was
observed: for the latter, this compound caused an effect similar
to that of compound 13, also suggesting an uncompetitive
mechanism of action with respect to the cofactor (i.e., increasing
the affinity of the enzyme for the cofactor). This interpretation was
confirmed by the results of comparative fitting (Table 2) that
showed uncompetitive inhibition with respect to the cofactor
NAD
+ as the most likely mode of inhibition for both compounds.
Crystal structure of the 15-PGDH homodimer
We were interested to explore whether the structure of 15-
PGDH could provide insights into the observed mechanisms of the
newly discovered inhibitors. After several unsuccessful crystalliza-
tion attempts with constructs bearing different tags fused to the N-
or C-terminus, respectively, it was possible to grow crystals in
presence of NADH from a construct purified with a C-terminal
His6 tag and to determine for the first time the structure of the
homodimer of 15-PGDH in a complex with its cofactor at a
resolution of 1.65 A ˚ (Figure 5 and Supplemental Table S2). This
resolution is not high enough to distinguish the reduced state of the
cofactor from its oxidized form [39]. It is, however, unlikely that
the structure of 15-PGDH contained NADH considering the time
necessary to generate the crystals and the known short half-life of
NADH in solution, despite the addition of the cofactor in its
reduced state. The protein shows the a/b folding pattern that is
highly conserved among the short-chain dehydrogenases/reduc-
tases (SDR), where a central b-sheet consisting of 8 strands is
Table 2. Global fitting of substrate titration data to different modes of inhibition (CM, competitive inhibition; UM, uncompetitive
inhibition; NM, noncompetitive inhibition; MM, mixed-mode inhibition).
PGE2 NAD
+
Compound 13 72 61 13 72 61
Competitive (CM) 0.8669 0.9299 0.9845 0.8764 n.d. 0.9507
Uncompetitive (UM) 0.9784 0.9680 0.9742 0.9664 n.d. 0.9837
Noncompetitive (NM) 0.9777 0.9734 0.9800 0.9655 n.d. 0.9834
Mixed-mode (MM) 0.9797 0.9736 0.9866 0.9675 n.d. 0.9841
Preferred* MM NM MM UM N/A UM
Sum-of-squares F-test UM vs. MM:
p=0.0133
UM vs. NM:
N/A
$
CM vs. NM:
N/A
$
UM vs. NM: N/A
$ N/A UM vs. NM: N/A
$
NM vs. MM:
p=0.0017
NM vs. MM:
p=0.3515
CM vs. MM:
p=0.0001
UM vs. MM:
p=0.0654
N/A UM vs. MM: p=0.1058
Displayed are the fit residual Chi
2 values, as well as probabilities of selected modes in comparison, from sum-of-squares F-testing.
*Analyses performed using PRISM 5.03 (GraphPad, Inc.). The threshold for rejection of the null-hypothesis (i.e., ‘‘The less complicated model is correct.’’) was set to
p=0.05.
$Both models with an equal number of degrees of freedom.
doi:10.1371/journal.pone.0013719.t002
Figure 5. Structure of the homodimer of human 15-PGDH in
complex with NAD
+ (PDB: 2GDZ). Displayed are the two protomers
with their backbones in grey and blue, respectively. The cofactor is
depicted in a ball-and-stick representation and color-coded by atom
type (green, carbon; red, oxygen; blue, nitrogen; orange, phosphate).
The C-terminus of each protomer whose residues originate from the
cloning procedure (see text) is highlighted in orange.
doi:10.1371/journal.pone.0013719.g005
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[18,40]. In the crystallized construct the last ten amino acids from
the 15-PGDH sequence are missing, leaving Tyr256 as the last
native amino acid. Instead, the cloning procedure resulted in the
fusion of nine non-natural amino acids (Gly-Ser-Lys-Glu-Asn-Leu-
Tyr-Phe-Gln) to the C-terminus remaining after cleavage of the
tag. In the structure of the dimer the artificial C-terminus of one
protomer is folded over the top of the opposing protomer
(highlighted in orange in Figure 5), with a number of residues
engaging in interactions with side chains of the other protomer,
notably between Phe264 and Tyr217. One cofactor molecule per
protomer is located in the center of the molecule (in ball-and-stick
representation in Figure 5). The acidic residue Asp36 forms
hydrogen bonds to the 29- and 39-hydroxyl groups of the adenine
ribose moiety, while Asp64 forms a hydrogen bond to the amino
group of the adenine moiety (supplementary information Figure
S2). The nicotinamide moiety of NAD
+ is positioned close to the
catalytic tetrad (Asn107, Ser138, Tyr151 and Lys155), competent
for the hydride transfer from the S-side of C4 to the substrate
following the reaction mechanism conserved among all SDRs
[31,40–42].
Docking of inhibitors to the 15-PGDHNNAD
+ complex
All attempts to co-crystallize the inhibitors with 15-PGDH were
unsuccessful. Therefore, we explored the inhibitor binding modes
by computational docking of the compounds to the structure of the
15-PGDHNNAD
+ complex. Docking experiments were carried out
using the structure of a single protomer, to avoid the artifactual
occupancy of the substrate pocket by the C-terminus of the
opposing protomer (see above). This structure offers a large
volume for binding of the inhibitors, notably a hydrophobic pocket
close to the nicotinamide moiety of the NAD
+, flanked by Ile195,
Leu192, Ile211 and Ile215 (indicated by a green mesh in
Figures 6A and 6B). An elongated tunnel leads to the exterior of
the protein, formed by Phe185, Met213, Leu139, Met143 and
Val145.
We identified plausible binding modes with well-defined side
chain interactions which, interestingly, were similar for all three
inhibitors, despite their structural differences (Figures 6A and 6B,
supplementary information Figure S3). Binding of compound 61
appears to be driven by interaction of the imidazo-pyridine ring
with the catalytic Ser138 and Tyr151 residues, while the bromo-
substituent projects into the hydrophobic pocket. The cyanobenzyl
group is accommodated in the substrate tunnel (Figure 6A). For
compound 13, the amide carbonyl also interacts with the catalytic
residues Ser138 and Tyr151, while the piperidine ring fits snugly
into the adjacent hydrophobic pocket. The remainder of the
molecule is accommodated along the tunnel towards solvent, with
the side chain of Phe185 providing a stacking opportunity for the
central benzimidazole moiety of 13 (Figure 6B). The binding
mode found for compound 72 is similar, with the triazole moiety
mimicking the amide carbonyl of compound 13 in accepting
hydrogen bonds from both Ser138 and Tyr151 (supplementary
information Figure S3). The fused azepine ring occupies the
proximal hydrophobic pocket, and the remaining biaryl moiety
extends into the substrate tunnel, again with the possibility for
stacking between the pyrrole ring of 72 and Phe185.
Discussion
Selective, high-affinity inhibitors for human 15-hydroxyprosta-
glandin dehydrogenase (15-PGDH) are desirable as tools to
facilitate the mapping of prostaglandin signaling pathways in vitro
and in vivo. Using a quantitative high-throughput screen approach
we have found several new chemotypes that inhibit 15-PGDH
with high affinity. Detailed biophysical analyses have demonstrat-
ed the strong stabilizing effect of these molecules on the enzyme.
Based on the results from our detailed kinetic analyses a number of
inhibition modes appeared possible, but the data are consistent
with compounds 13 and 72 not inhibiting competitively, while a
competitive mechanism of inhibition appeared likely for com-
pound 61.
In order to gain better understanding of the distinct mechanisms
of action of the inhibitors, it is helpful to examine the catalytic
mechanism of 15-PGDH. The SDR enzymes have been shown to
follow a common sequential ordered bi-bi-reaction mechanism,
involving sequential cofactor binding, substrate binding, catalysis,
product release, and finally release of co-product [31,40], as shown
in the reaction coordinate (Figure 7). In analogy with other SDRs,
binding of the NAD
+ cofactor is expected to alter the local
electrostatic environment of the catalytic Tyr151 residue, favoring
the deprotonated state. After substrate binding, the reaction
proceeds by deprotonation of the substrate 15-OH group by
Tyr151, facilitating hydride transfer from the substrate to NAD
+,
and forming the product complex consisting of protonated
Tyr151, NADH, and ketone.
One of the inhibitor chemotypes identified from the high
throughput screen is a series of imidazopyridines, represented by
the most potent analogue 61, with an IC50 of 25 nM and an
estimated Ki of 5 nM. The biophysical data show a strong
preference for 61 in stabilizing 15-PGDH complexed with NAD
+
as compared with NADH.
Figure 6. Binding of the inhibitors 61 (A) and 13 (B) in the active site of 15-PGDH as predicted by docking studies. The view shows a
cut-through into the substrate pocket of 15-PGDH, with the volume of the pocket indicated by a green mesh. Key amino acid residues (see text) are
labeled. Compounds and amino acid sidechains are in ball and stick representation, with the atoms color-coded: blue, nitrogen; red, oxygen; silver,
bromide; white, carbon atoms in side chains; yellow, carbon atoms in compounds; green, carbon atoms in the cofactor. The figures were created
using ICM (Molsoft, LLC).
doi:10.1371/journal.pone.0013719.g006
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competitive mechanism of inhibition by compound 61. The
docking directs the imidazopyridine group into hydrogen bonding
interactions with the catalytic residues Tyr151 and Ser138. In the
co-complex with NAD
+, as discussed above, the deprotonated
form of Tyr151 is favored: the resultant oxyanion is able to
interact with the protonated form of the pyridine ring, while the
hydroxy group of Ser138 is able to donate a hydrogen bond to the
adjacent imidazole nitrogen. The much weaker stabilization
observed with NADH implies that the protonated form of
Tyr151 interacts considerably more weakly with the pyridyl
nitrogen.
In addition to providing a convincing basis for interaction of the
heterocyclic motif with the enzyme’s catalytic machinery, this
binding orientation also favorably directs the bromo-substituent
into the nearby hydrophobic pocket, and places the S-linked
cyanobenzyl group into the substrate tunnel leading towards the
exterior of the protein, which contains side chains available for
stacking interactions (Phe185, Tyr217). Taken together, the data
argue that the position for binding of compound 61 along the
reaction coordinate of 15-PGDH is at step 2, i.e., occurs to the
complex of 15-PGDHNNAD
+ (left panel in Figure 7). This
interpretation is consistent with the observed uncompetitive
mechanism of action with respect to NAD
+, since the higher
affinity of the inhibitor compared to the substrate is expected to
increase the affinity for NAD
+.
The majority of the remaining inhibitor hits fall into three
structural clusters (clusters 1, 2 and 4; supplementary information
Table S1), all containing an amide moiety as the common feature
(Figure 2). Structure-activity relationships indicate that activity is
favored when the nitrogen of the amide forms part of a saturated
heterocycle, most commonly piperidine. In all of the active amides
identified, the carbonyl is linked to a ring, which is aromatic in the
most potent analogues. The highest potency is achieved when this
ring is linked to a further aryl ring, with a variety of linkers being
tolerated. In compound 13, this linker is incorporated into the
central fused benzimidazole ring system.
The results of the docking experiments are consistent with the
observed structure-activity relationships and provide help with the
decision about which of the mechanisms of inhibition that are
possible according to the kinetic analyses would be most likely for
the inhibitors. In the model of compound 13 docked into 15-
PGDH, the oxygen of the amide carbonyl presents two lone pairs
that can accept hydrogen bonds from both the catalytic Ser138
Figure 7. Proposed mechanism of prostaglandin dehydrogenation (after [31]) and inhibitory mechanisms of action for compounds
61 and 13. Compound 61 mimics the substrate (left panels), consistent with experimental data showing favored binding to the NAD
+-bound form
of 15-PGDH, and its competitive mechanism of inhibition with respect to PGE2. Compound 13 mimics the product of oxidation (right panels),
consistent with its favored binding to the NADH-bound form of 15-PGDH, and its uncompetitive mechanism of inhibition with respect to PGE2.
doi:10.1371/journal.pone.0013719.g007
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of the PGE2 substrate. Tyr151 is only able to donate this hydrogen
bond when protonated, which is favored by binding of NADH,
while binding of NAD
+ favors the deprotonated state. Hence,
compound 13 acts as a product analogue in the sequential ordered
bi-bi catalysis mechanism, and a noncompetitive mode of
inhibition with respect to PGE2 and an uncompetitive mode with
respect to NAD
+ would be expected [43]. Our kinetic analysis is
consistent with this mode, identifying uncompetitive inhibition
with respect to the cofactor, while equal probability was found for
noncompetitive, uncompetitive and mixed-type inhibition with
respect to the substrate (Table 2). Uncompetitive inhibition by the
compounds of the series with respect to NAD
+ is, furthermore,
consistent with the observed enhanced stabilization of 15-PGDH
when the latter is bound to NADH as compared with NAD
+; this
stabilization of product-bound 15-PGDH ultimately results in a
suppression of enzymatic turnover.
The preference for small alicyclic amides is also explained by
the docking model: the piperidine moiety of compound 13 is
relatively tightly accommodated in the hydrophobic pocket
adjacent to the catalytic residues (Figure 6B). Consistent with this
binding mode, inhibitory potency is weaker for secondary or
tertiary straight-chain amides, and further diminished or abolished
with bicyclic amides that can clearly not be accommodated in this
pocket (see Figure 2). As described above, the structure-activity
relationships indicate that activity is retained with a variety of
groups attached to the amide carbonyl carbon atom, although
there is a preference for aromatic groups, and in general these
groups are substituted in such a way as to be able to adopt an
extended conformation. Such a conformation is consistent with the
docking mode, placing the extended group into the substrate
tunnel leading towards the exterior of the protein. The availability
of side chain groups capable of stacking interactions (Phe185,
Tyr217) adds further support to this proposed binding mode
(Figure 6).
Compound 72 shares aspects of its mechanism with compound
13, notably a strong preference for NADH in co-stabilization of
15-PGDH (Figures 3 and 4A) and a cofactor-uncompetitive
inhibition mechanism. With respect to the substrate PGE2 the
kinetic analysis favored the noncompetitive mode, consistent with
the expectation for a product-analogous binding mode (see above).
Although compound 72 does not contain an amide group, the
fused 1,2,4-triazole is capable of acting as a bioisostere, with a lone
pair of electrons on each of the adjacent nitrogen atoms mimicking
the two lone pairs of the carbonyl oxygen in 13 (Supplementary
Information Figure S3). Thus, in the docking experiments, the
triazole moiety accepts two hydrogen bonds from Ser138 and the
protonated form of Tyr151; the remaining hydrophobic and
stacking interactions are remarkably similar to those modeled for
compound 13. Therefore, both compounds 13 and 72 bind at step
4 along the 15-PGDH reaction coordinate (Figure 7), mimicking
the product, favoring co-complex formation with NADH and
behaving in an uncompetitive manner with respect to the PGE2
substrate.
The compound library used for screening of 15-PGDH in this
study has been, so far, tested in screens against over 320 targets
(http://pubchem.ncbi.nlm.nih.gov/). This list includes two other
proteins that are involved in prostaglandin signaling, the EP2
prostaglandin-E2 receptor and the M1-muscarinic receptor. The
list also includes two SDR enzymes, hydroxyacyl dehydrogenase
(HADH2, also known as type-10 hydroxysteroid dehydrogenase,
HSD17b10; PubChem Assay ID 886) and type-4 hydroxysteroid
dehydrogenase (HSD17b4; PubChem Assay ID 893), and a
medium-chain dehydrogenase/reductase (MDR), aldehyde dehy-
drogenase 1 (ALDH1A1; PubChem Assay ID 1030), each of
which was tested using a similar experimental protocol to that used
for 15-PGDH. As the results in Table 3 show, all lead inhibitors
identified in this study were largely inactive against ALDH1A1:
compounds 61 and 72 showed a flat response, while compound 13
displayed only a shallow curve with an approximate IC50 of
36 mM. Against the two hydroxysteroid dehydrogenases
(HSD17b10 and HSD17b4), both compounds 13 and 72 were
inactive up to the top concentration of 57.5 mM.
In summary, the new inhibitor chemotypes identified in this
study provide a set of tools, with complementary mechanisms of
inhibition, for functional studies on the role of 15-PGDH in
prostaglandin signaling pathways. The lead compounds that have
been characterized in detail exhibit nanomolar affinities. The
existence of disease scenarios involving over-activation of 15-
PGDH and in which selective inhibition of the enzyme would be
beneficial, is currently unclear. Work published by Tai and co-
workers suggested that certain prostate cancers might involve
higher-than-normal activity of 15-PGDH [44], and for such cases
application of inhibitors based on the chemotypes identified in this
study may prove useful. The potential utility of the probes is
reinforced by the low cross-reactivity of these compounds in
screens against multiple targets, among them receptors with a role
in prostaglandin signaling and dehydrogenase enzymes utilizing
the same cofactors, suggesting selectivity of the inhibitors for 15-
PGDH. The availability of multiple inhibitors with diverse
chemical structures for cellular studies enhances confidence in
any response observed being due to on-target effects; the likelihood
for such diverse compounds having an identical off-target activity
profile is very small. While it is difficult to anticipate differences in
the cellular response between inhibitors showing contrasting
modes of action, one might expect the noncompetitive compounds
to demonstrate inhibition independently of the substrate concen-
tration. This may help to avoid problems similar to those
encountered, for example, with ATP-competitive protein kinase
inhibitors, where high inhibitor concentrations are required in
cells to compete against the endogenous co-factor. Finally, in this
work we present the novel crystal structure of human 15-PGDH,
which will serve as a basis for further studies on the function,
mechanism and inhibitor design for this enzyme.
Materials and Methods
Cloning, Expression and Purification
The protein was expressed in E. coli BL21(DE3)-R3 cells, from a
synthetic DNA sequence comprising residues 3–256 of the human
HPGD gene (GenBank identifier: 1203982). Cloning into the p15
vector added a TEV-cleavable (*) C-terminal His6 tag (gsken-
lyfq*ghhhhhh) and four extra amino acids, MAHM, at the N-
terminus. The protein was purified using immobilized Ni-affinity
Table 3. Selectivity profiling of key inhibitors against related
dehydrogenase/reductase enzymes.
Compound CID IC50/nM
15-PGDH ALDH1A1 HADH2 HSD17b4
13 4249877 56 36000* .57500 .57500
72 3717642 89 .57500 .57500 .57500
61 4251360 141 .57500 n.d. n.d.
*Maximal response 70% inhibition.
doi:10.1371/journal.pone.0013719.t003
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and size exclusion chromatography. As judged by SDS-PAGE, the
sample was .95% pure; the correct molecular weight was
confirmed using electrospray mass spectrometry. The protein
was frozen in aliquots in liquid nitrogen and stored at 280uC until
use.
Quantitative high-throughput screening (qHTS)
The 160,182-member library consisted of compounds from the
National Institutes of Health Molecular Libraries Small Molecule
repository (NIH MLSMR), prepared as 10 mM stock solutions in
384-well plates and delivered by Galapagos Biofocus DPI (South
San Francisco, CA, http://mlsmr.glpg.com), from the NCGC
internal exploratory collection comprising several commercially
available libraries of known bioactives, as well as from libraries
provided by commercial and academic collaborators. Details on
the library composition and its formatting for qHTS have been
published elsewhere [27,29,45].
The enzymatic reaction was performed in 50 mM Tris-HCl
pH 8.0, containing 0.01% Tween 20. Final reactions comprised
20 nM 15-PGDH, 1 mM NAD
+ and 30 mM PGE2. The high-
throughput screen was performed on a fully integrated robotic
system (Kalypsys Inc, San Diego, CA) as described elsewhere [45].
Library compounds, arrayed as seven-point inter-plate concentra-
tion series [29], were screened from the lowest (3.5 nM) to the
highest (57.5 mM) concentration, with plates containing DMSO
only, serving to note any systematic drifts in the signal,
interspersed evenly throughout the screen (approximately every
50 plates). Briefly, 3 mL of reagents were dispensed into 1536-well
Greiner black solid-bottom assay plates using integrated nanoliter
solenoid-technology dispensers [45]. Compounds and controls
(23 nL) were transferred via Kalypsys pintool equipped with
1,536-pin array (10-nL slotted pins; V&P Scientific, Palo Alto,
CA). After a 15-minute incubation (to allow for interaction
between compound and enzyme), a 1-mL substrate addition step
initiated the reaction. Kinetic data were collected on a ViewLux
High-throughput CCD imager (Perkin-Elmer) equipped with
standard UV fluorescence optics (exc. 340 nm, em. 450 nm).
Starting fluorescence intensity and the change in fluorescence
over the two-minute initial rate period were recorded for every
well. Screening data were normalized against no-enzyme (64 wells,
columns 3 and 4) and no-compound (32 wells located in column 1)
controls, and concentration-response relationships were derived as
described previously [46]. A four-parameter Hill equation [47]
was fitted to the concentration-response data using publicly
available algorithms (http://www.ncgc.nih.gov/pub/openhts/
curvefit/). Similarity clustering of active compounds and SAR
(structure-activity relationship) derivation were performed as
described previously [46].
Kinetic analysis and inhibitor mechanism of action
studies
Kinetic studies were performed in 100 mM Tris buffer pH 8.0,
containing 0.01% Tween-20 and 10 nM 15-PGDH enzyme.
NAD
+ and PGE2 were applied from stock concentrations of 100 or
2 mM, respectively, in 500 mM Tris/HCl, pH 8.0. All inhibitor
compounds were dissolved in 10% (v/v) DMSO at varying
concentrations from which they were applied at 1:5 ratio (resulting
in a final concentration of 2% (v/v) DMSO in all assays). For each
experiment an aliquot of purified enzyme was thawed freshly and
pre-diluted to 10 mM in buffer I (5 mM Tris/HCl, pH 8.0,
150 mM NaCl, 0.01% Tween-20). All experiments were per-
formed in white 384-well PCR microplates (Bio-Rad Laboratories,
Inc.) in final assay volumes of 20 mL. Twelve-point compound
titrations were set up from serially diluted stock solutions in 10%
(v/v) DMSO. Before starting the reactions by addition of 30 mM
PGE2 substrate and 200 mM NAD
+ in buffer I (from injectors built
into the spectrometer, PolarStar Omega, BMG Labtech GmbH),
the compounds were incubated in the wells of the plate with
enzyme for ten minutes at the experimental temperature of 25uC.
Experiments comprising substrate titrations, from serially diluted
stock solutions in buffer I, were started by injection of buffer I
containing enzyme and NAD
+, while cofactor titrations were set
up in assay buffer containing 30 mM PGE2 substrate and started
by injection of enzyme in buffer I. The reduction of NAD
+ was
followed by monitoring fluorescence emission at 460 nm, excited
at 355 nm (10 nm bandwidth filters, PolarStar Omega, BMG
Labtech GmbH), at a reading frequency of 22 s/point or 12 s/
point for compound- or substrate/cofactor titrations, respectively.
The initial rates recorded in compound titrations were plotted
against -log[compound], and non-linear regression (Levenberg-
Marquardt) fitting of the dose-response curve to the Hill equation
[47] was performed to derive the IC50, using PRISM 5.0
(GraphPad Software, Inc.). For substrate/cofactor titrations,
curves with initial rates plotted against the concentration of
substrate or cofactor were fitted to the Michaelis-Menten
equation, to derive maximal activities, Vmax, and Michaelis
constants, Km. Fitting qualities were judged from the goodness of
fit (R
2.0.98).
Differential Scanning Fluorimetry (DSF)
Studies to assess the thermal stability of human 15-PGDH in
presence of compounds were performed as described previously
[30], with variations. Briefly, the protein was diluted to a final
assay concentration of 1 mM in 100 mM Tris buffer pH 8.0,
containing 0.01% Tween-20 and 1:1000 SYPRO orange dye
(Invitrogen). The final assay volume was 10 mL, with or without
200 mM of either NAD
+ or NADH. Compounds were added at a
ratio of 1:5 from appropriate stock solutions in 10% (v/v) DMSO
to comprise either 50 or 250 mM final concentrations. Heat
denaturation curves were recorded using a RT-PCR instrument
(Mx3005p, Agilent) applying a temperature gradient of 2uC/min.
Analysis of the data was performed using DSF ANALYSIS 2.5
(ftp://ftp.sgc.ox.ac.uk/pub/biophysics) and PRISM 5.0 (Graph-
Pad Software, Inc.).
Chemical Synthesis of compounds
Compounds were synthesized following established procedures,
from starting materials and reagents purchased from Aldrich
Chemical Co. (supplementary information Text S1). The identity
of the compounds was confirmed by analytical thin layer
chromatography (TLC), nuclear magnetic resonance (NMR) and
high-resolution mass spectrometry.
X-ray crystallography
For crystallization of human 15-PGDH, purified protein was
concentrated by ultrafiltration to 17 mg/mL (Vivaspin, cut-off:
30 kDa). Prior to crystallization NADH (Sigma) was added to a
concentration of 5 mM to the concentrated protein in a volume of
100 nL. The solution was then mixed with 100 nL of crystalliza-
tion solution containing 30% (w/v) PEG-1000 and crystals were
obtained at 4uC using the sitting drop vapour diffusion technique.
Crystals were transferred to a cryo-protectant consisting of a fifth
of 100% (v/v) glycerol and four fifths of well solution, and flash-
frozen in liquid nitrogen. A dataset extending to a resolution of
1.65 A ˚ was collected on an R-AXIS HTC imaging plate area
detector mounted on an F-RE SuperBright rotating anode
generator (Rigaku MSC) operating at 45 kV and 45 mA
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integrated and scaled using MOSFLM v6.2.5 [48] and SCALA
v5.0 (implemented in the CCP4 suite [49]). Initial phases were
calculated by molecular replacement implemented by PHASER
v1.3.1 [50] using an ensemble of three SDR structures (PDB codes
1WMB [51], 1IY8 [52] and 1ZK3 [53]) as search models over 50
cycles of automated model building using ARP/wARP [54].
Water molecules were automatically picked by ARP/wARP and
later checked manually for appropriate density and hydrogen-
bonding pattern. The final rounds of manual model building and
refinement were carried out in COOT [55] and REFMAC
v5.02.0005 [56], respectively (supplementary information Table
S2). The coordinates of the final model and structure factors were
deposited with the PDB accession ID 2GDZ. The structural
information in this article can also be viewed as an enhanced
version in which the text of the article is integrated with interactive
3D representations and animated transitions, available on the
PLoS website (Datapack S1). A web plugin is required to access
this enhanced functionality. Instructions for the installation and
use of the web plugin are available in supplementary information
Text S2.
Molecular Docking
Docking was performed using GLIDE (Schrodinger, LLC) [57]
and the structure of 15-PGDH was prepared using the software’s
default minimization protocols. Docking grids were generated
using a box around Ser138 in the catalytic site. For docking to the
NAD
+ complex, Tyr151 was kept de-protonated; for docking to
the NADH complex NAD
+ was changed to NADH with a OPLS-
2005 force field [58] and a hydrogen constraint to Tyr151 was
used. Ligands (substrate and inhibitors) were prepared with the
LIGPREP and IONIZER tools in GLIDE, at pH 7.0+/22.0, to
determine the ionization states of the ligands. All inhibitors were
docked using GLIDE-SP and the top 5 scored poses were kept.
The binding poses were visually inspected and hydrogen bond
patterns were analyzed in order to determine the best pose.
Supporting Information
Table S1 Structural clustering of 87 compounds re-tested after
qHTS, with their potency in 24-point titrations compared to their
effects on 15-PGDH thermal stability.
Found at: doi:10.1371/journal.pone.0013719.s001 (0.15 MB
PDF)
Table S2 Data collection and structural refinement statistics for
human 15-PGDH.
Found at: doi:10.1371/journal.pone.0013719.s002 (0.11 MB
PDF)
Figure S1 Miniaturized screening assay for 15-PGDH. A.
Activity heatmaps showing the assay miniaturization to a 4 ml
volume in 1536-well format (increasing concentrations to the
right). B. Plot of the Z’ factor associated with each plate of the pilot
concentration-response screen of the LOPAC1280 library per-
formed to validate hit reproducibility. C. Molecular structure of
the control inhibitor GW5074 that was added as a 16-point
dilution series in duplicate between 57.5 mM and 1.75 nM into the
second column of every assay plate (panel D). The average IC50
for the compound was 10.4 mM and the associated minimum
significant ratio was approx. 1.5. E. Example of a fluorescent
inhibitor (applied at between 3.5 nM and 57.5 mM) on the time
course of NAD+-reduction upon injection of PGE2.
Found at: doi:10.1371/journal.pone.0013719.s003 (0.28 MB
PDF)
Figure S2 Binding of the cofactor NAD+ in the active site of
human 15-PGDH. The acidic residue Asp36 forms hydrogen
bonds to the 29- and 39-hydroxyl groups of the adenine ribose
moiety, while Asp64 forms a hydrogen bond to the amino group of
the adenine moiety. The nicotinamide moiety of NAD+ is
positioned close to the catalytic tetrad (Asn107, Ser138, Tyr151
and Lys155).
Found at: doi:10.1371/journal.pone.0013719.s004 (0.08 MB
PDF)
Figure S3 Binding of inhibitor 72 in the active site of 15-PGDH
as predicted by docking studies. The view shows a cut-through into
the substrate pocket of 15 PGDH, with the volume of the pocket
indicated by a green mesh. Key amino acid residues are labelled.
The figures were created using ICM (Molsoft, LLC).
Found at: doi:10.1371/journal.pone.0013719.s005 (0.07 MB
PDF)
Text S1 Methods used in the chemical syntheses of the three
lead compounds.
Found at: doi:10.1371/journal.pone.0013719.s006 (0.17 MB
PDF)
Text S2 Instructions for installation and use of the required web
plugin (to access the online enhanced version of this article).
Found at: doi:10.1371/journal.pone.0013719.s007 (0.46 MB
PDF)
Datapack S1 Standalone iSee datapack - contains the enhanced
version of this article for use offline. This file can be opened using
free software available for download at http://www.molsoft.com/
icm_browser.html.
Found at: doi:10.1371/journal.pone.0013719.s008 (ICB)
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